الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
Alopecia areata (AA) is a disease that causes marked cosmetic deformity and
psychological morbidity, leading to hair loss on the scalp, face and body.The suspected
etiopathogenesis include immune system dysfunctions, hereditary factors, infectious and
psychological factors.
In a healthy hair follicle, there is a high expression level of various
immunosuppressive molecules such as Insulin-like Growth Factor (IGF)-I. In contrast, the
epithelium of hair follicles in AA patients shows a decrease in immunosuppressive
molecules; a sign of possible change in immune modulation in the AA-affected skin.
Androgenetic alopecia (AGA), the most common type of baldness, is a hereditary
thinning of the hair induced by androgen in genetically susceptible men that has its onset in
late adolescence.
IGF-1 gene expression is enhanced by androgens. In androgen-responsive tissue,
IGF-1 may act locally to positively mediate the induction of 5(-reductase enzyme to form
dihydrotestosterone. This action of IGF-1 is essential for androgenetic alopecia.
IGFBP-3 regulates IGF-1 signaling by binding to it and acting as a competitive
inhibitor for IGF-1.In addition to these IGF-dependent effects, IGFBP-3 is believed to have
an IGF-independent inhibitory effect on cell growth that is mediated through a specific cell
membrane receptor.
The aim of this study was to evaluate the role of serum level of both (IGF1) and
(IGFBP3) in Patients with alopecia areata (AA) and androgenetic alopecia (AGA).
The present study included thirty patients with alopecia areata, thirty patients with
male and female pattern hair loss (androgenetic alopecia) and thirty age and sex matched
normal control subjects. Venous samples were taken for measurement of serum
concentration of IGF1, IGFBP3.
Exclusion criteria included: Subjects with a history of acne vulgaris, diabetes
mellitus, hypertension, cardiovascular disease (CVD), polycystic ovary syndrome (PCOS),
pseudoacanthosis nigricans, obesity (BMI 6 30 kg/m2), metabolic syndrome, Pregnancy,
use of contraceptive drugs, cancer. All the previously mentioned disorders can affect the
serum level of IGF1 and IGFBP3.
All subjects were subjected to history taking with general and dermatological
examination, serum level of IGF1 and IGFBP3 were measured using for both Enzymelinked
immunosorbent assay (ELISA).
The results presented in our study demonstrate that a statistical significant difference in
the level of IGF-1, IGFBP3 between patients and control as IGF1 level was significantly
higher in AGA group while lower in